Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Operating Leases (2020 - 2025)

10x Genomics' Operating Leases history spans 6 years, with the latest figure at $73.4 million for Q4 2025.

  • For Q4 2025, Operating Leases changed 0.07% year-over-year to $73.4 million; the TTM value through Dec 2025 reached $73.4 million, changed 0.07%, while the annual FY2025 figure was $73.4 million, 0.07% changed from the prior year.
  • Operating Leases for Q4 2025 was $73.4 million at 10x Genomics, down from $76.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $99.0 million in Q2 2022 and bottomed at $70.6 million in Q1 2025.
  • The 5-year median for Operating Leases is $79.9 million (2024), against an average of $82.2 million.
  • The largest annual shift saw Operating Leases soared 39.81% in 2022 before it decreased 13.57% in 2024.
  • A 5-year view of Operating Leases shows it stood at $76.8 million in 2021, then grew by 12.09% to $86.1 million in 2022, then dropped by 2.66% to $83.8 million in 2023, then decreased by 12.55% to $73.3 million in 2024, then increased by 0.07% to $73.4 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Operating Leases are $73.4 million (Q4 2025), $76.4 million (Q3 2025), and $86.7 million (Q2 2025).